CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. Our team has over 25 years’ experience in oncology and molecular cell biology and are using our expertise and experience in these areas to develop value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets
CV6 Therapeutics is developing value-based, first-in-class medications that are scalable to address global unmet medical needs in the oncology and inflammatory disease markets
CV6 Announces Initiation of Patient Dosing in Phase 1a Clinical Trial Evaluating the Investigational First-In-Class, Specific dUTPase Inhibitor CV6-168 Belfast, UK, 15 August 2024 – CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and inflammatory diseases by developing novel, first-in-class, small molecules targeting Uracil-DNA […]
Find Out More